Lexicon Pharmaceuticals Inc RELIEF-PHN-1 Call Transcript
Good day, and welcome to the Lexicon Pharmaceuticals Inc. top line results for LX9211 from the RELIEF-PHN-1 trial conference call. (Operator Instructions) . After today's presentation, there will be an opportunity to ask questions. Please note that this event is being recorded. I would now like to turn the conference over to Mr. Jeff Wade. Please go ahead, sir.
Good afternoon. I'm Jeff Wade, Lexicon's President and Chief Financial Officer. And joining me on the call today are Lonnel Coats, Lexicon's Chief Executive Officer; and Dr. Craig Granowitz, our Senior Vice President and Chief Medical Officer. Earlier this afternoon, we issued a press release announcing top line results of our RELIEF-PHN-1 Phase II study of LX9211 in postherpetic neuralgia. A webcast of this call, along with the slide presentation is available on our website. And during this call, we will review the information provided in the press release and then use the remainder of our time to answer your questions.
Before
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |